CVSIOTCPharmaceutical PreparationsFiscal year ends December 31
CV Sciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.01−0.00 (-21.13%)
Close on Oct 19, 2026
- Market cap
- $2.30M
- P/E (TTM)
- –
- Dividend yield
- –
CV Sciences, Inc. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Consumer Products Segment | – | – | – | – | $20.05M | $24.43M | $53.70M | $48.24M | $20.68M | $11.06M | – | – |
| Specialty Pharmaceutical Segment | – | – | – | – | $0 | $0 | $0 | $0 | $0 | $0 | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Consumer Products Segment | – | – | – | – | -$12.66M | -$20.22M | -$13.42M | $11.17M | -$4.15M | -$12.36M | – |
| Specialty Pharmaceutical Segment | – | – | – | – | -$5.79M | -$2.38M | -$3.82M | -$926.00K | -$709.00K | -$712.79K | – |
By product or service
By region
From the segment and revenue-disaggregation notes of CV Sciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.